Treatment of motor complications – end-of-dose phenomenon 1, 1h before meals or 1,5h after meals to take L-dopa preparation, to avoid dietary protein to affect its absorption and through the BBB. 2, if the dose of levodopa is large, you can increase the number of times of taking the drug, the dose of each dose is reduced, and the total daily dose remains unchanged . If the original dose is not large, the dose of each dose will remain unchanged, the number of doses will be increased, and the total daily dose will be increased. 4. The standard tablet will be changed to a controlled-release tablet, the dose will be increased by 20-30%, the duration of the action of L-dopa will be prolonged, and longer half-life dopamine agonists such as pramipexole and tesudanol will be added. 5.Add COMTI drugs: entacapone, tolcapone. 6.Adding MAO-B inhibitors: rasagiline, selegiline. 7.Surgical treatment: DBS: STN. Treatment of motor complications-switching phenomenon 1.Dopamine agonists, or levodopa extended-release agents can be tried. 2.Micro pump continuous infusion of L-dopa methyl ester, ethyl ester, or dopamine agonist. Treatment of Motor Complications-Freezing Phenomenon 1, If it occurs at the end of the L-dopa agent phase with other signs of PD, increasing a single dose of L-dopa may result in symptomatic improvement. 2, If it occurs in the open phase, reducing the L-dopa dose and adding a DR agonist or MAO-BI may be effective. 3, Some patients may also improve with skill training. Treatment of motor complications-isokinetic disorder Management of isokinetic disorder: dose peak isokinetic disorder. 1, Reduce each compounded levodopa dose 2, Reduce levodopa dose (when monotherapy) and add DR agonist. 3, Add COMT inhibitor. 4, Add amantadine. 5, Change the compound levodopa controlled-release tablets to standard tablets to avoid the cumulative effect of controlled-release tablets. Treatment of anisotropy: Biphasic anisotropy – occurs at the beginning and at the end of the levodopa dose. 1, change the compound levodopa controlled-release tablets to standard tablets or aqueous solvents , to relieve the beginning of the dose of anisotropy. 2.Adding long half-life DR agonists or COMT inhibitors that prolong the plasma clearance half-life of L-dopa alleviates end-of-dose anisotropy and may also alleviate beginning-of-dose anisotropy. 3, Micropump continuous infusion of DR agonists or L-dopa methyl ester and ethyl ester to ameliorate anisocoria and symptom fluctuations. 4, Adenosine A2A receptor antagonist, in clinical trials. Dystonia – painful spastic foot dystonia presenting in the morning. 1, Compound levodopa controlled release or long-acting dopamine agonist before bedtime. 2.Take compound levodopa standard tablets or water-soluble tablets before getting up. 3.Dystonia – the “open” period. Indications for surgical treatment 1, typical Parkinson’s disease, levodopa preparations have been effective. 2.After the complete drug treatment, the symptoms can no longer be controlled or dyskinesia comorbidity occurs, and the adjustment of drugs can not be improved. 3, The history of the disease is at least 5 years. There is no severe cognitive or psychiatric impairment or cerebral atrophy.